Risperidone versus placebo for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 12, 2016, Pages

  Rattehalli, Ranganath D ^a   Zhao, Sai ^b   Li, Bao Guo ^c   Jayaram, Mahesh B ^d   Xia, Jun ^e   Sampson, Stephanie ^e  

^a Logan Hospital   (Australia)

^b Systematic Review Solutions Ltd   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIPARKINSON AGENT; BENZODIAZEPINE; CHOLESTEROL; CLOZAPINE; CREATINE KINASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPNOTIC SEDATIVE AGENT; LORAZEPAM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRAZEPAM; PROLACTIN; PSYCHOTROPIC AGENT; RISPERIDONE; TRIACYLGLYCEROL; ZOLPIDEM; NEUROLEPTIC AGENT; PLACEBO;

AGITATION; AKATHISIA; ANXIETY DISORDER; ARTHROPATHY; ASTHENIA; BACKACHE; BARNES AKATHISIA SCALE; BIOSIS; BLURRED VISION; BODY MASS; BRADYCARDIA; BRADYKINESIA; CINAHL; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEATH; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; DYSMENORRHEA; DYSPEPSIA; DYSTONIA; ECG ABNORMALITY; ELEVATED BLOOD PRESSURE; EMBASE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HUMAN; HYPERSALIVATION; INFECTION; INSOMNIA; MEDLINE; MENTAL HEALTH; MUSCLE HYPERTONIA; MYALGIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSONISM; PHARYNGITIS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCINFO; QTC INTERVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESTLESSNESS; REVIEW; RHINITIS; RIGIDITY; RISK ASSESSMENT; SCHIZOPHRENIA; SEDATION; SINUSITIS; SOMNOLENCE; SYSTEMATIC REVIEW; TACHYCARDIA; TARDIVE DYSKINESIA; TOOTH DISEASE; TREMOR; UPPER RESPIRATORY TRACT INFECTION; VAGINITIS; VOMITING; WAIST CIRCUMFERENCE; WEIGHT GAIN; XEROSTOMIA; META ANALYSIS; ORAL DRUG ADMINISTRATION; PUBLISHING;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; HUMANS; PLACEBOS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA;

EID: 85006285304     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006918.pub3     Document Type: Review

References (456)

1. Bachmann M, Ramsey M, Buchanan RW, Conley RC, Weiner E. Clozapine treatment of schizophrenic patients. www.clinicaltrials.gov (accessed 9 October 2013). [3089763; NCT00056498]
2. Borison R. Risperidone versus haloperidol versus placebo in the treatment of schizophrenia. Clinical report 1991. [3089765]
3. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. Journal of Clinical Psychopharmacology 1995;15(Suppl 1):S36-S44. [3089773; MEDLINE: 7537286]
4. Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. Journal of Clinical Psychopharmacology 1997;17(4):298-307. [3089767; MEDLINE: 9241010]
5. Chouinard G, Arnott W. An antidyskinetic effect of risperidone. 9th World Congress of Psychiatry; 1993 Jun 6-12; Rio de Janeiro, Brazil. 1993:22. [3089768; MEDLINE: 94350925]
6. Chouinard G, Arnott W. Antidyskinetic effect of risperidone in chronic schizophrenic patients. Clinical Neuropharmacology 1992;15(Suppl 1 Pt B):266. [3089769; MEDLINE: 94350925]
7. Chouinard G, Arnott W. The effect of risperidone on extrapyramidal symptoms in chronic schizophrenic patients. Biological Psychiatry 1992;31:158. [3089770; MEDLINE: 94350925]
8. Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. Journal of Clinical Psychopharmacology 1993;13(1):25-40. [3089771; MEDLINE: 93253120]
9. Chouinard G, Vainer JL, Beauclair L. Dose regimens of neuroleptics in negative symptoms. 19th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1994 Jun 27-Jul 1; Washington DC, USA 1994;10(3 Suppl 1):S363. [3089772; MEDLINE: 94350925]
10. Downing A M, Kinon B J, Millen B A, Zhang L, Liu L, Morozova M A, et al. A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia. BMC Psychiatry 2014;14:351. [4295811]
11. Durgam S, Starace A, Li D, Migliore R, Ruth A, Nemeth G, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res 2014;152:450-7. [4295813]
12. Geffen Y, Anand R, Keefe R, Davidson M. Results of phase 2b eagle trial; a double blind placebo control study evaluating the efficacy and safety of bl-1020, a gaba enhanced antipsychotic for the treatment of schizophrenia. Schizophrenia Research 2010;117(2-3):212. [3089775]
13. Heisterberg J, Barbato LM, Yeung PP, Shapira NA. Lipid profile among patients with schizophrenia randomized to bifeprunox, placebo, or risperidone: a comparison of results. Schizophrenia Bulletin 2007;33(2):432-3. [3089777]
14. Yeung PP, Barbato LM, Heisterberg J, Shapira NA. Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Schizophrenia Bulletin 2007;33(2):466-7. [3089778]
15. Yeung PP, Shapira NA, Heisterberg J. Changes in safety parameters in patients with schizophrenia treated with bifeprunox, placebo, or risperidone. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1, Colorado Springs, Colorado, USA. 2007. [3089779]
16. Honer W. International study of improving treatment for the most severely ill with schizophrenia. www.clinicaltrials.gov (accessed 9 October 2013). [3089781; NCT00272584]
17. Ereshefsky L, Anderson C, True J, Saklad SR, Reisenman C, Toney G, et al. Plasma concentration of oral risperidone and active metabolite in schizophrenics. Pharmacotherapy 1993;13(3):292. [3089783; LMD96402]
18. Lindenmayer JP, The Risperidone Study Group. Incidence of EPS with risperidone compared with haloperidol and placebo in patients with chronic schizophrenia. 146th Annual Meeting of the American Psychiatric Association; 1993 May 22-27; San Francisco, California, USA. 1993. [3089784; MEDLINE: 94350925]
19. Marder S. Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. Clinical Research Report RIS-INT-3 1991. [3089785; MEDLINE: 1375802]
20. Marder SR. Risperidone: clinical development: North American results. Clinical Neuropharmacology 1992;15(Suppl 1 Pt A):92A-3A. [3089788; MEDLINE: 92361850]
21. Marder SR. Risperidone: efficacy. Journal of Clinical Psychiatry 1994;12:49-52. [3089789; MEDLINE: 94350925]
22. Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Journal of Clinical Psychological Medicine 1997;58(12):538-46. [3089786]
23. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. American Journal of Psychiatry 1994;151(6):825-35. [3089787; EMBASE 1994202181]
24. McEvoy JP. Efficacy of risperidone on positive features of schizophrenia. Journal of Clinical Psychiatry 1994;55(5 Suppl):18-21. [3089790; EMBASE 1994182002]
25. Meibach R. Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France. USA, 1992:28-9. [3089791; LMD94893]
26. Meibach RC, The Risperidone Study Group. A fixed dose, parallel group study of risperidone vs. haloperidol vs. placebo. Schizophrenia Research 1993;9(2, 3):245. [3089792; MEDLINE: 94350925]
27. NCT00249132 Risperidone versus haloperidol versus placebo in the treatment of chronic schizophrenia. clinicaltrials.gov/show/NCT00249132 (2005). [3089793]
28. Schooler NR. Negative symptoms in schizophrenia: assessment of the effect of risperidone. Journal of Clinical Psychiatry 1994;55(Suppl 5):22-8. [3089794; MEDLINE: 94350925]
29. Simpson GM, Lindenmayer JP. Extrapyramidal symptoms in patients treated with risperidone. Journal of Clinical Psychopharmacology 1997;17(3):194-201. [3089795; MEDLINE: 97313564; PsycINFO 1997-06350-009]
30. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2003;64(11):1342-8. [3089797]
31. Pai Y-M, Yu S-C, Lin C-C. Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [3089798]
32. Pai Y-M, Yu S-C, Lin C-C. Risperidone in reducing tardive dyskinesia: a double-blind, placebo-controlled study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [3089799]
33. Potkin SG, Gutierrez R. Safety and efficacy of once-daily risperidone in the treatment of schizophrenia. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA. 1997. [3089801]
34. Potkin SG, Kujawa M, Carson WH, Saha AR, Ali M, Ingenito G. Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research 2003;60(1):300. [3089803]
35. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry 2003;60(7):681-90. [3089804]
36. Saha A, Carson W, Ali M, Dunbar G, Ingenito G. Efficacy and safety of aripiprazole and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001. [3089805]
37. Yeung P, Kujawa M, Carson WH, Saha A, Alid M, Ingenito G. Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Schizophrenia Research 2002;53(3 Suppl 1):185-6. [3089806]
38. Yeung P, McQuade RD, Carson WH, Saha A, Ali MW, Ingenito G. Aripiprazole and risperidone versus placebo in schizophrenia. European Psychiatry 2002;17(Suppl 1):102s. [3089807]
39. Yeung PP, Carson WH, Saha A, McQuade RD, Ali M, Stringfellow JC, et al. Efficacy of aripiprazole, a novel antipsychotic, in schizophrenia and schizoaffective disorder: results of a placebo-controlled trial with risperidone. European Neuropsychopharmacology 2001;11(3):259. [3089808]
40. Gharabawi GM, Greenspan A, Rupnow MFT, Kosik-Gonzalez C, Bossie CA, Zhu Y, et al. Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry 2006;6(45):1-7. [3089810]
41. Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y, McLemore J, Gharabawi G. Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA. 2005:Nr279. [3089811]
42. Greenspan A, Kosik-Gonzalez C, Moreau-Mallet V, Bossie CA, Rupnow MFT, Zhu Y, et al. Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study. European Neuropsychopharmacology 2005;15(Suppl 3):S503. [3089812]
43. NCT00061802 A randomized, double blind study to evaluate the efficacy and safety of two atypical antipsychotics vs placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder. clinicaltrials.gov/show/NCT00061802 (2003). [3089813]
44. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MFT, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization. Schizophrenia Research 2006;85(1-3):254-65. [3089814]
45. Potkin SG, Greenspan A, Kosik-Gonzalez C, Bossie C, Rupnow M, Zhu Y, et al. A placebo-controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia. Schizophrenia Bulletin 2005;31:501. [3089815]
46. Rupnow M, Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y, Gharabawi G, et al. Polypharmacy in schizophrenia: data from a randomized, double-blind study. Proceedings of the 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA. 2005. [3089816]
47. Stahl S, Rupnow M, Greenspan A, Kosik-Gonzalez C, Zhu Y, Gharabawi G. Use and cost of polypharmacy in schizophrenia: data from a randomized, double-blind study of risperidone and quetiapine. Neuropsychopharmacology 2004;29(Suppl 1):S227. [3089817]
48. Potkin S, Fleming K, Binneman B, Keller DS, Alphs L, Panagides J. Asenapine improves cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. Proceedings of the 160th Annual Meeting of the American Psychiatric Association; 2007 May 19-24; San Diego, CA 2007. [3089819]
49. Potkin S, Fleming K, Binneman B, Keller S. Asenapine cognitive function effects in acute schizophrenia: a placebo- and risperidone-controlled trial. Schizophrenia Bulletin 2007;33(2):454. [3089820]
50. Potkin SG, Cohen M, Jina AS, Nettler S, Alphs L, Panagides J. Asenapine efficacy during acute episodes of schizophrenia: a randomized placebo and risperidone controlled trial. Proceedings of the 44th American College of Neuropsychopharmacology; 2005 December 11-15, Waikoloa, Hawaii 2005. [3089821]
51. Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. Journal of Clinical Psychiatry 2007;68(10):1492-500. [3089825]
52. Potkin SG, Cohen M, Panagides J, Jina A. Asenapine safety and tolerability in acute schizophrenia: a placebo- and risperidone-controlled trial. European Neuropsychopharmacology 2006;16(Suppl 4):S401. [3089822]
53. Potkin SG, Cohen M, Panagides J, Jina AS. Asenapine efficacy in acute schizophrenia: a randomized, placebo- and risperidone-controlled trial. International Journal of Neuropsychopharmacology 2006;9(Suppl 1):S275. [3089823]
54. Potkin SG, Cohen M, Panagides J, Jina AS. Asenapine efficacy, safety, and tolerability in the treatment of acute schizophrenia: a randomized, placebo- and risperidone-controlled trial. Biological Psychiatry 2006;59(8 Suppl):154S. [3089824]
55. Akdede BB, Anil Yaciolu AE, Alptekin K, Turgut TI, Tumuklu M, Yazici MK, et al. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition. Journal of Clinical Psychiatry 2006;67(12):1912-9. [3089827]
56. Yagcioglu AE, Kivircik Akdede BB, Turgut TI, Tumuklu M, Yazici MK, Alptekin K, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. Journal of Clinical Psychiatry 2005;66(1):63-72. [3089828]
57. Adler LA, Rotrosen J, Edson R, Lavori P, Lohr J, Hitzemann R, et al. Vitamin E treatment for tardive dyskinesia. Archives of General Psychiatry 1999;56(9):836-41. [3089830]
58. Adler LA, Rotrosen J, Lavori P, Edson R. Vitamin E treatment of TD: development of a VA cooperative study. Biological Psychiatry 1994;35:730-1. [3089831]
59. Caligiuri MP, Lohr JB, Rotrosen J, Adler L, Lavori P, Edson R, et al. Reliability of an instrumental assessment of tardive dyskinesia: results from VA Cooperative Study 394. Psychopharmacology 1997;132(1):61-6. [3089832]
60. Akhondzadeh S, Mackinejad K, Ahmadi-Abhari SA, Alem ZM. Does the addition of lamotrigine to risperidone improve psychotic symptoms and cognitive impairments in chronic schizophrenia?. Therapy 2005;2(3):399-406. [3089834]
61. Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B. Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophrenia Research 2007;90(1-3):179-85. [3089836]
62. Anwunah IJ, Mitropoulou V, Bushnoe L, Siever LJ. Risperidone treatment for schizotypal personality disorder. Proceedings of the 51st Institute on Psychiatric Services; 1999 Oct 25-Nov 2; New Orleans, Louisiana, USA. 1999. [3089838]
63. Ayd FJ. Risperidone treatment for schizotypal personality disorder. International Drug Therapy Newsletter 2001;36(8):58. [3089840]
64. Azorin J, Toumi M, Sloth-Nielsen M. Sertindole is well tolerated and superior to risperidone with respect to efficacy in patients with schizophrenia. Schizophrenia Research 2003;60(1):271-2. [3089842]
65. Azorin JM, Toumi M, Sloth-Nielsen M. Sertindole is well tolerated and superior to risperidone with respect to efficacy in patients with schizophrenia. European Neuropsychopharmacology 2002;12(Suppl 3):S300. [3089843]
66. Azorin J-M, Strub N, Loft H. A double-blind, controlled study of sertindole versus risperidone in the treatment of moderate-to-severe schizophrenia. International Clinical Psychopharmacology 2006;21(1):49-56. [3089845]
67. Bai Y-M, Yu S-C, Chen J-Y, Lin C-Y, Chou P, Lin C-C. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study. International Clinical Psychopharmacology 2005;20(2):79-85. [3089847]
68. Bai Y-M, Yu S-C, Lin C-C. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2003;64:1342-8. [3089848]
69. Baker RA, Jin N, Ali MW, Forbes RA, Offord SJ, Carson WH, Sanchez R, McQuade RD, Rahman Z. Long-term effects (up to 4 years) of aripiprazole on maintenance treatment for schizophrenia or schizoaffective disorder: A pooled open-label extension of two clinical trials. Schizophrenia research 2012;136:S154. [4295815]
70. Basson B, Kennedy J, Tollefson G, Tran P, Beasley C, Bymaster F. The comparative anti muscarinic like adverse event profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis. Proceeding of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999. [3089850]
71. Basson B, Kinon BJ, Gilmore JA, Taylor CC, Tollefson GD, Czekalla J. Factors influencing weight change in patients with schizophrenia treated with olanzapine verus haloperidol or risperidone. Journal of Psychopharmacology 2000;14(3 Suppl):A60. [3089851]
72. Basson BR, Kennedy JS, Tran PV, Beasley CM, Bymaster FP, Tollefson GD. The comparative anti-muscarinic like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis. Schizophrenia Research 1999;36(1-3):270. [3089852]
73. Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. Journal of Clinical Psychiatry 2001;62(4):231-8. [3089853]
74. Beasley C Jr, Tollefson GD, Beuzen JN, Dellva MA, Sanger TM, Paul S. Acute and long-term results of the North American double-blind olanzapine trial. Proceedings of the 4th International Conference on Schizophrenia: Breaking Down the Barriers; 1996 Oct 6-9; Vancouver, Canada. 1996. [3089855]
75. Beasley C, Tran P, Beuzen JN, Tamura R, Dellva MA, Bailey J, et al. Olanzapine versus haloperidol: long-term results of the multi-center international trial. Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996. [3089856]
76. Beasley C, Tran P, Satterlee W, Tollefson G, Lu Y, Kuntz A, et al. Olanzapine versus placebo, results of the United States double-blind olanzapine trial. Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996. [3089857]
77. Beasley CM. Safety of olanzapine. Journal of Clinical Psychiatry 1997;15(2):19-21. [3089867]
78. Beasley CM Jr, Sanger T, Satterlee W, Tollefson G, Tran P, Hamilton S. Olanzapine versus placebo - results of a double-blind, fixed dose olanzapine trial. Psychopharmacology 1996;124(1-2):159-67. [3089858]
79. Beasley CM, Berg PH, Dananberg J, Kwong KC, Taylor CCM, Breier A. Treatment-emergent potential impaired glucose tolerance and potential diabetes with olanzapine compared to other antipsychotic agents and placebo. Biological Psychiatry 2001;49(8):121S. [3089859]
80. Beasley CM, Dellva MA, Tamura RN, Morgenstern H, Glazer WM, Ferguson K, et al. A randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol. British Journal of Psychiatry 1999;174:23-30. [3089860]
81. Beasley CM, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology 1997;7(2):125-37. [3089861]
82. Beasley CM, Sayler ME, Keisler GM, Potvin JH, Sanger TM, Tollefson GD. The influence of pharamacotherapy on self-directed and externally-directed aggression in schizophrenia. Schizophrenia Research 1998;29(1-2):28. [3089862]
83. Beasley CM, Sowell MO, Carlson C, Mukhopadhyay N, Dananberg J, Henry R, et al. Prospective evaluation of insulin sensitivity by the hyperinsulinemic, euglycemic clamp in healthy volunteers treated with olanzapine, risperidone or placebo. Schizophrenia Research 2003;60(1):309. [3089863]
84. Beasley CM, Sutton VK, Hamilton SH, Walker DJ, Dossenbach M, Taylor CC, et al. A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse. Journal of Clinical Psychopharmacology 2003;23(6):582-94. [3089864]
85. Beasley CM, Tollefson G, Tran P, Satterlee W, Sanger T, Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropyschopharmacology 1996;14(2):111-23. [3089865]
86. Beasley CM, Tollefson GD, Dellva MA, Tamura R, Glazer WM, Morgenstern H. The differential risk of tardive dyskinesia with olanzapine. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Ontario, Canada. 1998. [3089866]
87. Bondolfi G, Baumann P, Dufour H. Treatment-resistant schizophrenia - clinical experience with new antipsychotics. European Neuropsychopharmacology 1996;6(Suppl 2):S21-5. [3089869]
88. Bondolfi G, Baumann P, Patris M, May J, Billeter U, Dufour H, et al. A randomized double-bind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30-Oct 4; Venice, Italy. 1995. [3089870]
89. Bondolfi G, Baumann P, Patris M, May JP, Billeter U, Dufour H. A randomised double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. Proceedings of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20-25; Miami, Florida, USA. 1995. [3089871]
90. Bondolfi G, Baumann P, Patris M, May JP, Billeter U, Dufour H. A randomized double-blind trial of risperidone versus clozapine for treatment-resistant chronic schizophrenia. Proceedings of the Workshop on Critical Issues in the Treatment of Schizophrenia; 1995 Mar 10-12; Florence, Italy. 1995. [3089872]
91. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. American Journal of Psychiatry 1998;155(4):499-504. [3089873]
92. Borison R. Risperidone versus haloperidol in acute exacerbations of chronic schizophrenia. Proceedings of the 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France. 1992. [3089876]
93. Borison R, Pathiraja A, Diamond B, Meibach R. Risperidone and schizophrenia. Biological Psychiatry 1991;29:417. [3089875]
94. Borison RL, Diamond BI, Augusta GA. Serotonin modulation of dopaminergic-medicated extrapyramidal side effects. Neurology 1991;41(Suppl 1):396. [3089877]
95. Borison RL, Diamond BI, Pathiraja A, Meibach RC. Clinical profile of risperidone in chronic schizophrenia. Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan. 1991. [3089878]
96. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone - clinical safety and efficacy in schizophrenia. Psychopharmacology Bulletin 1992;28(2):213-8. [3089879]
97. Borison RL, Pathiraja AP, Diamond BI, Meibach RC. Risperidone in the treatment of acute exacerbation of chronic schizophrenia. Schizophrenia Research 1991;4(3):314-5. [3089880]
98. Borison Rl, Pathiraja AP, Diamond BI, Meibach RC. Antidopaminergic and antiserotonergic actions of risperidone in schizophrenia. Biological Psychiatry 1991;29(Suppl):114a. [3089881]
99. Boyer P, Lecrubier Y, Puech AJ. Treatment of positive and negative symptoms: pharmacologic approaches. In: Andreasen NC editor(s). Modern problems of pharmacopsychiatry. Vol. 24, Basel, Switzerland: S. Karger, 1990:152-74. [3089887]
100. Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. British Journal of Psychiatry 1995;166(1):68-72. [3089886]
101. Boyer P, Puech AJ. Determinants for clinical activity of neuroleptic drugs: chemical substances, doses, assessment tools [Modalities d'action clinique des neuroleptiques: substances, doses, instruments de mesure utilises]. Psychiatrie and Psychobiologie 1987;2(4):296-305. [3089889]
102. Boyer P, Puech AJ, Lecrubier Y. Double blind trial versus placebo of low dose amisulpride (Solian 50) in schizophrenia with exclusively negative symptoms. Preliminary analysis of results [Etude en double insu contre placebo de l'amisulpride (Solian (r) 50) a faible dose chez des schizophrenes purement deficitaires. Premiere analyse des resultats]. Annales de Psychiatrie 1988;3(3):321-5. [3089888]
103. Brecher M. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31-Nov 4; Paris, France. 1998. [3089891]
104. Brecher M, The Risperidone Olanzapine Study Group. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. 1998. [3089892]
105. Brecher M, The Risperidone-Olanzapine Study Group. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder conference abstract. Schizophrenia Research 1999;36(1-3):271. [3089893]
106. Cada DJ, Levien T, Baker DE. Risperidone long-acting injection. Hospital Pharmacy 2004;39(4):353-62. [3089895]
107. Carson W, Cornblatt B, Saha A, Ali M, Kern R, Green M. Neurocognitive benefits of aripiprazole versus olanzapine in stable psychosis. European Neuropsychopharmacology 2002;12(Suppl 3):S291. [3089897]
108. Carson W, McQuade R, Saha A, Torbeyns A, Stock E. Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. European Neuropsychopharmacology 2002;12(Suppl 3):S288. [3089898]
109. Carson W, Pigott T, Saha A, Ali M, McQuade RD, Torbeyns AF, et al. Aripiprazole vs placebo in the treatment of stable, chronic schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [3089899]
110. Carson WH, Ali M, Dunbar G, Ingenito G, Saha AR. A double-blind, placebo-controlled trial of aripiprazole and haloperidol. Schizophrenia Research 2001;49(1, 2):221-2. [3089900]
111. Carson WH, Ali M, Saha AR, Dunbar GC, Ingenito G. A double-blind, placebo-controlled trial of aripiprazole and haloperidol in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [3089901]
112. Carson WH, Ingenito GG, Mcquade RD, Stock EG, Iwamoto T. Schizophrenia: safety / tolerability of aripiprazole. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [3089902]
113. Carson WH, Kane JM, Ali M, Dunbar GC, Ingenito G. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. European Neuropsychopharmacology 2000;10(Suppl 3):S309. [3089903]
114. Carson WH, Pigott TA, Saha AR, Ali MW, McQuade RD, Torbeyns AF, et al. Aripiprazole vs placebo in the treatment of chronic schizophrenia. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S187. [3089904]
115. Carson WH, Saha AR, Ali M, Dunbar GC, Ingenito G. Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. 2001. [3089905]
116. Carson WHJ, Saha AR, Ali M, Dunbar GC, Ingenito G. Aripiprazole and risperidone versus placebo in schizophrenia and schizoaffective disorder. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [3089906]
117. Casey D, Barbato LM, Heisterberg J, Yeung PP, Shapira NA. Results of a bifeprunox dose-finding study in patients with acutely exacerbated schizophrenia. Schizophrenia Bulletin 2007;33(2):425. [3089908]
118. Casey D, Saha A, Marcus R, Carson WH, McQuade RD, Torbeyns AF, et al. Aripiprazole versus placebo for relapse prevention in patients with chronic schizophrenia. Schizophrenia Research 2003;60(1):276. [3089909]
119. Casey D, Saha AR, Ali MW, Jody DN, Kujawa MJ, Stock EG, et al. Switching to aripiprazole monotherapy. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S187. [3089910]
120. Casey DE, Barbato LM, Heisterberg J, Yeung PP, Shapira NA. Results of a bifeprunox dose-finding study in patients with acutely exacerbated schizophrenia. Proceedings of the 11th International Congress on Schizophrenia Research; 2007 Mar 28-Apr 1, Colorado Springs, Colorado, USA 2007. [3089911]
121. Casey DE, Carson WH, Saha AR, Liebeskind A, Ali MW, Jody D, et al. Switching patients to aripiprazole from other antipsychotic agents: A multicenter randomized study. Psychopharmacology 2003;166(4):391-9. [3089912]
122. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropyschopharmacology 2003;28(1):182-92. [3089913]
123. Casey DE, Saha AR, Ali MW, Jody D, Kujawa MJ, Stock EG, et al. Switching to aripiprazole monotherapy. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [3089914]
124. Castle DJ, Jensen JKS. Management of depressive symptoms in schizophrenia: A pooled, post hoc analysis from the asenapine development program. Clinical Schizophrenia and Related Psychoses 2015;9:13-20. [4295817]
125. Chan H-Y, Lin W-W, Lin S-K, Hwang T-J, Su T-P, Chiang S-C, et al. Efficacy and safety of aripiprazole in the acute treatment of schizophrenia in Chinese patients with risperidone as an active control: a randomized trial. Journal of Clinical Psychiatry 2007;68(1):29-36. [3089919]
126. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. European Neuropsychopharmacology 2005;15(1):111-7. [3089921]
127. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tables. Schizophrenia Research 2002;53(3 Suppl 1):174. [3089922]
128. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Proceedings of the 11th Biennial Winter Workshop on Schizophrenia; 2002 Feb 24-Mar 1; Davos, Switzerland. 2002. [3089923]
129. Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, et al. Maintenance of efficacy when switching from oral risperdal to risperdal consta RIS-INT-61. Poster supplied by Company 2002. [3089924]
130. Ciliberto N, Bossie CA, Urioste R, Lasser RA. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. International Clinical Psychopharmacology 2005;20(4):207-12. [3089926]
131. Citrome L, Casey DE, Daniel DG, Wozniak P, Kochan LD, Tracy KA. Adjunctive divalproex and hostility among patients with schizophrenia receiving olanzapine or risperidone. Psychiatric Services 2004;55(3):290-4. [3089928]
132. Citrome LL, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Casey DE. Antipsychotic monotherapy versus combination treatment with valporate in hospitalized patients with acute schizophrenia: a double-blind, multi-center study. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [3089929]
133. Claus A, Bollen J, De Cuyper H, Eneman M, Malfroid M, Peuskens J, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatrica Scandinavica 1992;85(4):295-305. [3089931]
134. Conley RR, Brecher M, The Risperidone/Olanzapine Study Group. Risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorders. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31-Nov 4; Paris, France. 1998. [3089933]
135. Conley RR, Brecher MB, Olanzapine-Risperidone Study Group. Risperidone versus olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington DC, USA. 1999. [3089934]
136. Conley RR, Mahmoud R. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2001; Vol. 158, issue 5:765-74. [3089935]
137. Conley RR, Mahmoud R. Efficacy of risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. European Neuropsychopharmacology 2000;10(Suppl 3):S343. [3089936; 13th Congress of the European College of Neuropsychopharmacology [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P3021]
138. Conley RR, Mahmoud R. Efficacy of risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S151. [3089937]
139. Conley RR, Mahmoud R. Risperidone and olanzapine in people with schizophrenia or schizoaffective disorder: a randomised double-blind study. Poster supplied by Company 2001. [3089938]
140. Conley RR, Mahmoud R. Risperidone vs olanzapine in patients with schizophrenia & schizoaffective disorder. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30-Jun 2; Boca Raton, Florida, USA. 2000. [3089939]
141. Conley RR, Mahmoud R. Risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder: safety comparisons. European Neuropsychopharmacology 2000;10(Suppl 3):S342. [3089940; 13th Congress of the European College of Neuropsychopharmacology [CD-ROM]: Conifer, Excerpta Medica Medical Communications BV, 2000 P3020]
142. Conley RR, Mahmoud R. Risperidone vs. olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder: safety comparisons. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S151. [3089941]
143. Conley RR, Mahmoud R, Risperidone Study Group. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. Proceedings of the 10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 5-11; Davos, Switzerland. 2000. [3089942]
144. Conley RR, Mahmoud R, Risperidone Study Group. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective psychosis [Risperidon versus olanzapin bei patienten mit schizophrenie und schizoaffektiven psychosen]. Nervenheilkunde 2000;19(5):110-2. [3089943]
145. Conley RR, Mahmoud R, Risperidone Study Group. Risperidone vs. olanzapine in patients with schizophrenia and schizoaffective disorder. Biological Psychiatry 2000;47:32S. [3089944]
146. Conley RR, Mahmoud RA. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [3089945; NR1 Monday, May 15, 9:00 a.m.-10:30 a.m]
147. Conley RR, Mahmoud RA. Risperidone versus olanzapine in patients with schizophrenia and schizoaffective disorder. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA. 2000. [3089946]
148. Conley RR, Mahmoud RA. Risperidone vs olanzapine in patients with schizophrenia and schizo-affective disorder. International Drug Therapy Newsletter 2000;35(10):77-8. [3089947]
149. Cooper SJ, Butler A, Tweed J, Raniwalla J, Welch C. Zotepine in the prevention of relapse. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France. 1997. [3089949]
150. Cooper SJ, Butler A, Tweed JA, Welch CP, Wighton AJ, Appleby P, et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31-Nov 4; Paris, France. 1998. [3089950]
151. Cooper SJ, Butler A, Tweed JA, Welch CP, Wighton AJ, Appleby P, et al. Zotepine is effective in preventing recurrence in patients with chronic schizophrenia. Schizophrenia Research 2000;41(1):207-8. [3089951]
152. Cooper TB, Volavka J, Czobor P. Plasma drug level and clinical response. Journal of Clinical Psychopharmacology 1992;12(2):134-6. [3089952]
153. Cornblatt B, Kern RS, Carson WH, Ali MW, Luo X, Green M. Neurocognitive effects of aripiprazole versus olanzapine in stable psychosis. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S185. [3089954]
154. Cornblatt B, Kern RS, Carson WH, Stock E, Ali M, Ingenito G, et al. Neurocognitive effects of aripiprazole versus olanzapine in patients with stabile psychosis. Journal of Psychopharmacology 2002;16(Suppl 3):A15. [3089955]
155. Cornblatt B, Kern RS, Carson WH, Stock E, Ali M, Ingenito G, et al. Neurocognitive effects of aripiprazole versus olanzapine in patients with stable psychosis. Schizophrenia Research 2002;53(3 Suppl 1):27. [3089956]
156. Crawford AM, Beasley CM, Tollefson GD. Olanzapine - impact of an atypical antipsychotic candidate on prolactin release. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9, New York, New York, USA. 1996. [3089958]
157. Crawford AM, Beasley CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. European Neuropsychopharmacology 1997;7(Suppl 2):199. [3089959]
158. Crawford AM, Beasley CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophrenia Research 1997;26(1):41-54. [3089960]
159. Crawford AMK, Beasley CM, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentration. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [3089961]
160. Crawford AMK, Gomez JC, Beasley CM Jr, Tollefson GD. Olanzapine versus haloperidol: analysis of schizophrenic patients from the multi-center international trial. European Neuropsychopharmacology 1997;7:2.015. [3089962]
161. Csernansky J. Do novel antipsychotics optimize long term outcomes in schizophrenia. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S1. [3089968]
162. Csernansky J, Brecher M, Okamoto A. Risperidone vs haloperidol: relapse prevention in schizophrenia and schizoaffective disorders: a long-term double-blind comparison. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999. [3089964]
163. Csernansky J, Okamoto A. A long term double blind comparison of risperidone and haloperidol in stable outpatients with schizophrenia or schizoaffective disorder. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S155. [3089965]
164. Csernansky J, Okamoto A. Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: long term double blind comparison. Proceedings of the 22nd Collegium Internationale Neuro-Psychopharmacologicum Congress; 2000 Jul 9-13; Brussels, Belgium. 2000. [3089966]
165. Csernansky J, Okamoto A. Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: long term double blind comparison. Schizophrenia Research 2000;41(1):198. [3089967]
166. Csernansky JG, Mahmoud R, Brenner R, The Risperidone-USA-79 Study Group. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. The New England Journal of Medicine 2002;346(1):16-22. [3089969]
167. Csernansky JG, Okamoto A. Risperidone versus haloperidol for prevention of relapse in patients with schizophrenia and schizoaffective disorder: a long-term double blind comparison. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico. 1999. [3089972]
168. Csernansky JG, Okamoto A. Risperidone versus haloperidol for relapse prevention in schizophrenia and schizoaffective disorder: a long-term double-blind placebo controlled comparison. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30-Jun 2; Boca Raton, Florida, USA. 2000. [3089973]
169. Csernansky JG, Okamoto A. Risperidone vs haloperidol for relapse prevention in schizophrenia and schizoaffective disorder: a long-term double-blind comparison. Biological Psychiatry 2000;47:31-2S. [3089974]
170. Csernansky JG, Okamoto A, Brecher M. Risperidone vs haloperidol: prevention of relapse in schizophrenia. European Neuropsychopharmacology 1999;9:S268. [3089970]
171. Csernansky JG, Okamoto A, Brecher MB. Risperidone versus haloperidol for prevention of relapse in schizophrenia and schizoaffective disorder: a long-term, double-blind comparison. Proceedings of the 51st Institute on Psychiatric Services; 1999 Oct 25-Nov 2; New Orleans, Louisiana, USA. 1999. [3089971]
172. David S, Crawford AM, Breier A. Prolactin levels in olanzapine versus typical and atypical antipsychotics. European Neuropsychopharmacology 1998;8(Suppl 2):s229. [3089976]
173. David SR, Meehan KM, Sutton VK, Taylor CC. Treatment of negative symptoms with olanzapine in comparison with other novel antipsychotic agents. European Neuropsychopharmacology 1999;9:S292. [3089977]
174. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics 2000;22(9):1085-96. [3089978]
175. Davis JM, Chen N. Evidence of efficacy of risperidone in schizophrenia. Schizophrenia Research 2001;49(1-2):224-5. [3089980]
176. Davis SM, Koch GG, Davis CE, La Vange LM. Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the clinical antipsychotic trials of intervention effectiveness (CATIE) studies. Schizophrenia Bulletin 2003;29(1):73-80. [3089981]
177. Dossenbach M, Friedel P, Jakovljevic M, Hotujac L, Folnegovic V, Uglesic B, et al. Olanzapine versus fluphenazine - six weeks' treatment of acute schizophrenia. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [3089985]
178. Dossenbach M, Jakovljevic M, Folnegovic F, Uglesic B, Dodig G, Friedel P, et al. Olanzapine versus fluphenazine - 6 weeks treatment of anxiety symptoms during acute schizophrenia. Schizophrenia Research 1998;29(1, 2):203. [3089986]
179. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets; medical review part 1. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm 2002 (accessed 9 October 2013):1-50. [3089988]
180. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets; medical review part 2. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm. U.S. Food and Drug Administration CDER, 2002 (accessed 9 October 2013):50-110. [3089989]
181. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets; medical review part 3. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm. U.S. Food and Drug Administration CDER, 2002 (accessed 9 October 2013):111-75. [3089990]
182. Dubitsky GM, Harris R, Laughren T, Hardeman S. Abilify (aripiprazole) tablets; medical review part 4. www.fda.gov/cder/foi/nda/2002/21-436_Abilify.htm. U.S. Food and Drug Administration CDER, 2002 (accessed 9 October 2013):176-232. [3089991]
183. Edgell ET, Andersen SW, Grainger D, Wang J. Resource use and quality of life of olanzapine compared with risperidone: results from an international randomized clinical trial. Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. 1998. [3089993]
184. Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S92. [3089995]
185. Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. Pharmacoeconomics 2000;18(6):567-79. [3089996]
186. Edgell ET, Andersen SW, Johnstone BM, Dulisse B, Revicki D, Breier A, et al. Olanzapine versus risperidone: a prospective comparison of clinical and economic outcomes in schizophrenia. European Psychiatry 2000;15(Suppl 2):408s. [3089994]
187. Edgell ET, Grainger DL, Andersen SW, Wang J. Resource use and quality of life associated with olanzapine compared with risperidone. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Ontario, Canada. 1998. [3089997]
188. Edgell ET, Hamilton SH, Revicki DA, Genduso LA, Tollefson GD. Costs of olanzapine treatment compared with haloperidol for schizophrenia: results from a randomized clinical trial. Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-6; Glasgow, UK. 1998. [3089998]
189. Fleming K, Potkin SG, Binneman B, Keller D, Alphs L, Panagides J. Effects of asenapine on cognitive function in acute schizophrenia: a placebo- and risperidone-controlled trial. European Neuropsychopharmacology 2007;17(Suppl 4):S466. [3090000]
190. Friedman J, Adler D, Temporini H, Harvey P, Kemether E, Davis K. Alpha2 agonists enhance cognition of schizophrenia patients in combination with atypical but not typical neuroleptics. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S155. [3090002]
191. Friedman JI, Adler D, Temporini HD, Harvey PD, Kemether EM, Davis KL. Alpha-2 agonists enhance cognition of schizophrenia patients in combination with atypical but not typical neuroleptics. Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [3090003]
192. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Biological Psychiatry 2002;51:349-57. [3090004]
193. Friedman JI, Adler DN, Howanitz E, Harvey PD, Brenner G, Temporini H, et al. A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. Schizophrenia Research 2002;53(3 Suppl 1):9. [3090005]
194. Friedman JI, Adler DN, Howanitz E, Temporini H, Harvey PD, Davis KL. Effects of donepezil on cognition, symptoms, and movement disorders in patients with chronic schizophrenia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [3090006]
195. Friedman JI, Adler DN, Temporini HD, Harvey PD, Davis KL. Alpha-2 agonists enhance cognition of schizophrenic patients in combination with atypical but not typical neuroleptics. Proceedings of the 38th Annual Meeting of the American College of Neuropsychopharmacology; 1999 Dec 12-16; Acapulco, Mexico. 1999. [3090007]
196. Friedman JI, Adler DN, Temporini HD, Kemether E, Harvey PD, White L, et al. Guanfacine treatment of cognitive impairment in schizophrenia. Neuropyschopharmacology 2001;25(3):402-9. [3090008]
197. NCT00488163 Pilot study of atomoxetine to enhance cognition in patients with schizophrenia. clinicaltrials.gov/show/NCT00488163 (2007). [3090009]
198. Gismondi R, Meltzer H, Kujawa M, Carson W, Stringfellow J, Iwamoto T, et al. Aripiprazole versus perphenazine in treatment-resistant schizophrenia. Proceedings of the XXIVth Collegium Internationale Neuro-Psychopharmacologicum Congress; 2004 June 20-24, Paris, France 2004. [3090011]
199. Gregor K, Hamilton S, Edgell E. Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999. [3090017]
200. Gregor KJ, Allicar MP, Lilliu H, Olivier V, Le Pen C, Gavart S. An economic comparison of olanzapine versus haloperidol in the treatment of schizophrenia in France. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S161. [3090018]
201. Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. European Neuropsychopharmacology 1999;9(Suppl 1):S11. [3090019]
202. Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. European Neuropsychopharmacology 1999;9:S289. [3090020]
203. Gregor KJ, Hamilton SH, Edgell ET. Functional outcomes in schizophrenia: a European comparison of olanzapine and haloperidol. Schizophrenia Research 2000;41(1):189. [3090021]
204. Harvey K, Burns T, Sedgwick P, Higgitt A, Creed F, Fahy T. Relatives of patients with severe psychotic disorders: factors that influence contact frequency. Report from the UK700 trial. British Journal of Psychiatry 2001;178:248-54. [3090023]
205. Harvey P, Meltzer H, Green M. Long term cognitive effects of risperidone treatment in schizophrenia. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S154. [3090024]
206. Harvey P, Meltzer H, Green M. Risperidone cognitive effects in schizophrenia and schizoaffective patients. International Drug Therapy Newsletter 2001;36(8):59. [3090025]
207. Harvey P, Meltzer HY, Green MP. Cognitive effects of risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001. [3090026]
208. Harvey P, Melzer H, Green M. Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Biological Psychiatry 2001;49(8):123S. [3090027]
209. Harvey PD. Cognitive effects of risperidone and olanzapine in patients with schizophrenia. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25-29; Philadelphia, Pennsylvania, USA. 2000. [3090036]
210. Harvey PD. Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA. 2000. [3090035]
211. Harvey PD. Long-term cognitive effects of risperidone treatment in schizophrenia. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25-29; Philadelphia, Pennsylvania, USA. 2000. [3090037]
212. Harvey PD, Gharabawi G. Risperidone and cognition in schizophrenic elderly. Proceedings of the 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [3090028]
213. Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology 2003;169(3-4):404-11. [3090029]
214. Harvey PD, Lyons BE, Mahmoud R. Long term cognitive effects of risperidone. Schizophrenia Research 2000;41(1):200-1. [3090030]
215. Harvey PD, Mahmoud R, Meltzer HY, Green MP. Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. European Neuropsychopharmacology 2001;11(3):257. [3090031]
216. Harvey PD, Meltzer HY, Green M. Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [3090032]
217. Harvey PD, Meltzer HY, Green MF. Cognitive effects of risperidone and olanzapine in patients with schizophrenia or schizoaffective disorder. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30-Jun 2; Boca Raton, Florida, USA. 2000. [3090033]
218. Harvey PD, Meltzer HY, Green MF. Long-term cognitive effects of risperidone treatment in schizophrenia. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [3090034]
219. Hwang TJ, Lee S-M, Sun HJ, Lin H-N, Tsai S-J, Lee Y-C, et al. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. Journal of the Formosan Medical Association 2003;102(1):30-6. [3090039]
220. Hwang TJ, Chan HY, Lin WW, Lin SK, Hwu HG, Cheng MY, et al. Aripiprazole versus risperidone in the treatment of acutely relapsed patients with schizophrenia in Taiwan: a randomized controlled trial. European Neuropsychopharmacology 2005;15(Suppl 3):S497. [3090041]
221. Kane J, Carson Wh, Kujawa M, Stringfellow J, Marcus R, Sanchez R, et al. Aripiprazole in treatment-resistant schizophrenia: a 6-week double-blind comparison study versus perphenazine. Schizophrenia Research 2004;67(1):155-6. [3090043]
222. Kane J, Eerdekens M, Keith S, Lesem M, Karcher K, Lindenmayer J-P. Efficacy and safety of Risperdal Consta, a long-acting injection risperidone formulation RIS-USA-121. Promotional slides on file from Janssen-Cilag UK Ltd 2002. [3090044]
223. Kane J, Eerdekens M, Keith S, Lesem M, Karcher K, Lindenmayer J-P. Efficacy and safety of a novel long-acting risperidone formulation. European Psychiatry 2002;17(Suppl 1):S193. [3090045]
224. Kane J, Eerdekens M, Keith S, Lesem M, Karcher K, Lindenmayer J-P. Efficacy and safety of a novel long-acting risperidone microspheres formulation. Proceedings of the 11th Biennial Winter Workshop on Schizophrenia; 2002 Feb 24-Mar 1; Davos, Switzerland. 2002. [3090046]
225. Kane J, Eerdekens M, Keith S, Lesem M, Karcher K, Lindenmayer JP. Long-acting risperidone microspheres for treatment of patients with schizophrenia. European Neuropsychopharmacology 2001;11(3):291. [3090047]
226. Kane J, Eerdekens M, Keith SJ, Lesem M, Karcher K, Lindenmayer JP. Efficacy and safety of risperdal constatm, the long-acting injection risperidone formulation. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S188. [3090048]
227. Kane J, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Schizophrenia Research 2000;41(1):39. [3090049]
228. Kane JM. Preventing morbidity in first-episode schizophrenia. clinicaltrials.gov/ct2/show/NCT00000374 (accessed 16 Feb 2001). [3090060]
229. Kane JM. The latest advance in long-acting antipsychotic therapy. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [3090061]
230. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 2002;63(9):763-71. [3090050]
231. Kane JM, Conley RR, Keith SJ, Nasrallah HA, Turner M. Guidelines for the use of long-acting injectable atypical antipsychotics. Journal of Clinical Psychiatry 2004;65(1):120-31. [3090051]
232. Kane JM, Eerdekens M, Keith SJ, Lesem M, Karcher K, Lindenmayer J-P. Efficacy and safety of a novel long-acting risperidone microspheres formulation. Schizophrenia Research 2002;53(3 Suppl 1):174. [3090052]
233. Kane JM, Eerdekens M, Keith SJ, Lesem M, Karcher K, Lindenmayer JP. Long-acting injectable risperidone: Efficacy and safety. European Neuropsychopharmacology 2002;12(Suppl 3):S325. [3090053]
234. Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. American Journal of Psychiatry 2003;160:1125-32. [3090054]
235. Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [3090055; NR345 Tuesday, May 16, 3:00 p.m.-5:00 p.m]
236. Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S124. [3090057]
237. Kane JM, Ingenito G, Ali M. Efficacy of aripiprazole in psychotic disorders: comparison with haloperidol and placebo. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA. 2000. [3090056]
238. Kane JM, Potkin S, Buckley P, Daniel DG. Safety and efficacy of sertindole and risperidone in treatment resistant patients with schizophrenia. Schizophrenia Bulletin 2005;31:490. [3090058]
239. Kane JM, William HCJ, Kujawa MJ, Stringfellow J, Marcus RN, Sanchez R, et al. Aripiprazole vs perphenazine in treatment-resistant schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [3090059]
240. Kinon B, Basson B, Malcolm S, Breier A. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Proceedings of the 39th Annual Meeting of the New Clinical Drug Evaluation Unit; 1999 Jun 1-4; Boca Raton, Florida, USA. 1999. [3090063]
241. Kinon B, Basson B, Tollefson GD. Gender-specific prolactin olanzapine versus haloperidol in schizophrenia. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Ontario, Canada. 1998. [3090064; 151st Annual Meeting of the American Psychiatric Association [CD-ROM]: MARATHON Multimedia, 1988 NR449; 151st Annual Meeting of the American Psychiatric Association [CD-ROM]: MARATHON Multimedia, 1988 NR739]
242. Kinon B, Basson B, Tollefson GD. Gender-specific prolactin olanzapine versus haloperidol in schizophrenia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Ontario, Canada. 1998. [3090065]
243. Kinon B, Basson BR, Malcolm SK, Tollefson G. Strategies for switching from conventional antipsychotic drugs to olanzapine. Proceedings of the 152nd Annual Meeting of the American Psychiatric Association; 1999 May 15-20; Washington, DC, USA. 1999. [3090066]
244. Kinon B, Breier A, Malcolm S, Basson B. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Proceedings of the 11th World Congress of Psychiatry; 1999 Aug 6-11; Hamburg, Germany. 1999. [3090067]
245. Kinon BJ, Basson B, Hill AL, Berg PH. Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. European Neuropsychopharmacology 2000;10(Suppl 3):S305. [3090068]
246. Kinon BJ, Basson B, Szymanski K, Tollefson GD. Predictors of weight gain during olanzapine treatment. Proceedings of the 11th European College of Neuropsychopharmacology Congress; 1998 Oct 31-Nov 4; Paris, France. 1998. [3090069]
247. Kinon BJ, Basson B, Wang J, Malcolm SK. Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Schizophrenia Research 2000;41(1):194-5. [3090073]
248. Kinon BJ, Basson B, Wang J, Malcolm SK, Stauffer VL. Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. European Neuropsychopharmacology 2000;10(Suppl 3):S306. [3090070]
249. Kinon BJ, Basson B, Wang J, Malcolm SK, Stauffer VL. Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S155. [3090072]
250. Kinon BJ, Basson B, Wang J, Malcolm SK, Stauffer VL. Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Proceedings of the 40th Annual Meeting of the New Clinical Drug Evaluation Unit; 2000 May 30-Jun 2; Boca Raton, Florida, USA. 2000. [3090071]
251. Kinon BJ, Basson BR, Gilmore JA, Malcolm S, Stauffer VL. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine. Journal of Clinical Psychiatry 2000;61(11):833-40. [3090074]
252. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. Journal of Clinical Psychiatry 2001;62(2):92-100. [3090075]
253. Kinon BJ, Basson BR, Malcolm SK, Tollefson GD. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine conference abstract. Schizophrenia Research 1999;36(1-3):285-6. [3090076]
254. Kinon BJ, Basson BR, Wang J. Rapid reduction in hyperprolactinemia upon switching treatment to olanzapine from conventional antipsychotic drugs or risperidone. Proceedings of the 52nd Institute on Psychiatric Services; 2000 Oct 25-29; Philadelphia, Pennsylvania, USA. 2000. [3090078]
255. Kinon BJ, Basson BR, Wang J, Malcolm SK, Stauffer VL. Rapid reduction in hyperprolactinemia. Proceedings of the 153rd Annual Meeting of the American Psychiatric Association; 2000 May 13-18; Chicago, Illinois, USA. 2000. [3090077]
256. Kinon BJ, Basson MS, Tollefson GD. Gender-specific prolactin response to treatment with olanzapine versus haloperidol in schizophrenia. Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13; Davos, Switzerland 1998. [3090079]
257. Kinon BJ, Gilmore JA, Gottschalk LA. Continued improvement in quality of life despite weight change during olanzapine treatment. Proceedings of the 39th Annual Meeting of the American College of Neuropsychopharmacology; 2000 Dec 10-14; San Juan, Puerto Rico. 2000. [3090080]
258. Kinon BJ, Liu-Seifert H, Ahl J, Ahmed S, Baker RW. Longitudinal effect of olanzapine on fasting serum lipids: a randomized, prospective, 4-month study. Annals of the New York Academy of Sciences 2004;1032:295-6. [3090081]
259. Kinon BJ, Milton DR, Gilmore JA. Continued improvement in quality of life despite weight change during olanzapine treatment. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S154. [3090082]
260. Kinon BJ, Milton DR, Hill AL. Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. International Journal of Neuropsychopharmacology 2000;3(Suppl 1):S154. [3090084]
261. Kinon BJ, Milton DR, Hill AL, Williamson DJ. Effective resolution of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia with olanzapine. Journal of Psychopharmacology 2000;14(3 Suppl):A60. [3090083]
262. Kinon BJ, Roychowdhury SM, Milton DR, Hill AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. Journal of Clinical Psychiatry 2001;62(Suppl 2):17-21. [3090085]
263. Kinon BJ, Millen BA, Zhang L, McKinzie DL. Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. Biological psychiatry 2015;InPress:InPress. [4295819]
264. Lauriello J, McEvoy JP, Rodriguez S, Bossie CA, Lasser RA. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophrenia Research 2005;72(2-3):249-58. [3090087]
265. Lemmens P, de Smedt G, Gheuens J, Tritsmans L. Efficacy of risperidone in the treatment of schizophrenia. Proceedings of the 7th Biennial Winter Workshop on Schizophrenia; 1994 Jan 23-28; Les Diablerets, Switzerland 1994; Vol. 11, issue 2:106. [3090089]
266. Lieberman J, McEnvoy J, Stroup S. Protocol: comparative effectiveness of antipsychotic medications in patients with schizophrenia: revised in response to DSMB comments. National Institute of Mental Health. Chapel Hill, USA: University of North Carolina, 2000. [3090091]
267. Lieberman J, McEvoy J, Stroup S. Trial design summary: Comparative effectiveness of antipsychotic medications in patients with schizophrenia: Draft. National Institute of Mental Health. Chapel Hill, USA: University of North Carolina, 2002. [3090092]
268. Lieberman J, McEvoy JP, Perkins D, Hamer RH. Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone. European Neuropsychopharmacology 2005;15(Suppl 3):S525. [3090093]
269. Lieberman JA. Comparative effectiveness of antipsychotic medications in patients with schizophrenia (CATIE schizophrenia trial). clinicaltrials.gov/ct2/show/NCT00014001 2001 (accessed 9 October 2013). [3090100]
270. Lieberman JA. Research gaps and current research initiatives to improve the treatment of schizophrenia. Proceedings of the 156th Annual Meeting of the American Psychiatric Association; 2003 May 17-22; San Francisco, California, USA. 2003. [3090101]
271. Lieberman JA, Schneider LS, McEroy J, Pariot P, Stroup S, Adiao J, et al. Effectiveness trials of antipsychotic drugs. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [3090094; No. 103D]
272. Lieberman JA, Schneider LS, McEroy J, Pariot P, Stroup S, Adiao J, et al. Effectiveness trials of antipsychotic drugs. Proceeding of the 154th Annual Meeting of the American Psychiatric Association; 2001 May 5-10; New Orleans, Louisiana, USA. Marathon Multimedia, 2001. [3090095]
273. Lieberman JA, Stroup TS. Schizophrenia, VI: treatments. American Journal of Psychiatry 2003;160(10):1748. [3090098]
274. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Keefe R, Perkins DO, et al. CATIE trial results. European Neuropsychopharmacology 2006;16(Suppl 4):S184. [3090096]
275. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005;353(12):1209-23. [3090097]
276. Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. American Journal of Psychiatry 2003;160(8):1396-404. [3090099]
277. Lindstrom E, von Knorring L. Changes in single symptoms and separate factors of the schizophrenic syndrome after treatment with risperidone or haloperidol. Pharmacopsychiatry 1994;27(3):108-13. [3090103]
278. Loo H, Poirier Littre MF, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. British Journal of Psychiatry 1997;170:18-22. [3090105; MEDLINE: 9068769]
279. Lopez Ibor JJ, Ayuso JL, Gutierrez M, Guimon J, Herraiz ML, Chinchilla A, et al. Risperidone in the treatment of chronic schizophrenia: multicenter study comparative to haloperidol [Risperidona en el tratamiento de la esquizofrenia cronica: estudio multicentrico comparativo versus haloperidol]. Actas Luso Espanolas de Neurologia Psiquiatria y Ciencias Afines 1996;24(4):165-72. [3090107]
280. Lopez-Ibor JJ. Safety profile of risperidone in the multicentre trials. Proceedings of the 1st International Risperidone Investigators' Meeting; 1992 Mar 9-10; Paris, France. 1992. [3090109]
281. Palley risperidone sustained release tablets and olanzapine tablets in the treatment of exacerbations and readmission of patients with schizophrenia in a randomized double-blind placebo-controlled study. Chinese Journal of Mental Health 2011;23(05):560-3. [3090111]
282. Marder SR, Chouinard G, Davis JM. The clinical actions of risperidone. Proceedings of the 6th World Congress of Biological Psychiatry 1997;Jun 22-27:Nice, France. [4295821]
283. McClellan J. Risperidone for schizophrenia. Stanley Foundation Research Programs 2009. [3090113]
284. McClure MM, Koenigsberg HW, Reynolds D, Goodman M, New A, Trestman R, Silverman J, Harvey PD, Siever LJ. The effects of risperidone on the cognitive performance of individuals with schizotypal personality disorder. Journal of clinical psychopharmacology 2009;29:396-398. [4295823]
285. McKenna PJ. An international study of improving treatment for the most severely ill with schizophrenia. National Research Register 2004. [3090115]
286. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Correction. Journal of Clinical Psychiatry [linchuang jingshen yixue zazhi] 2004;65(8):1150. [3090117]
287. Nasrallah HA, Duchesne I, Mehnert A, Janagap C, Eerdekens M. Health-related quality of life in patients with schizophrenia during treatment with long-acting, injectable risperidone. Journal of Clinical Psychiatry 2004;65(4):531-6. [3090118]
288. NCT00034892 Efficacy and tolerability of olanzapine, quetiapine and risperidone in the treatment of first episode psychosis: a randomized double blind 52-week comparison. clinicaltrials.gov/ct2/show/NCT00034892 (2002) (accessed 9 October 2013). [3090120]
289. NCT00088075 A randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of risperidone for the treatment of schizophrenia in adolescents. clinicaltrials.gov/ct2/show/NCT00088075 (2004) (accessed 9 October 2013). [3090122]
290. NCT00202007 A multi-center, randomized, double-blind study, comparing with risperidone, to evaluate the efficacy and safety of aripiprazole in the treatment of patients with schizophrenia. clinicaltrials.gov/ct2/show/NCT00202007 (2005) (accessed 9 October 2013). [3090124]
291. NCT00249119 Risperidone in the treatment of chronic schizophrenic patients: an international multicentre double-blind parallel-group comparative study versus haloperidol. clinicaltrials.gov/ct2/show/NCT00249119 (2005) (accessed 9 October 2013). [3090126]
292. NCT00253136 Risperidone depot (microspheres) vs placebo in the treatment of subjects with schizophrenia. clinicaltrials.gov/ct2/show/NCT00253136 (2005) (accessed 9 October 2013). [3090128]
293. NCT00305474 Identification and treatment of the liability to develop schizophrenia. clinicaltrials.gov/ct2/show/results/NCT00305474 (2006) (accessed 9 October 2013). [3090130]
294. Nct02109562 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of RBP-7000 (90mg and 120mg) as a Treatment in Subjects With Acute Schizophrenia Over 8 Weeks (2 Subcutaneous Doses). http://Clinicaltrials.gov/show/NCT02109562. [4295825]
295. Peuskens J, Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. British Journal of Psychiatry 1995;166:712-26. [3090138]
296. Peuskens J, Kasper S. Amisulpride versus risperidone in schizophrenia: comparing clinical and functional outcome in a 6 months study. Proceedings of the 7th World Congress of Biological Psychiatry; 2001 Jul 1-6; Berlin, Germany. 2001. [3090140]
297. Peuskens J, Moller HJ. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. European Neuropsychopharmacology 2001;11(3):255. [3090142]
298. Pikalov A, Cucchiaro J, Ogasa M, Silva R, Hsu J, Xu J, Loebel A. Effect of lurasidone on weight and metabolic parameters: A comprehensive database analysis. Schizophrenia research 2012;136:S278. [4295827]
299. Rabinowitz J, Davidson M. Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophrenia Research 2001;50(1-2):89-93. [3090144]
300. Rein W, Fleurot O. Efficacy of amisulpride vs risperidone in the long-term treatment of chronic schizophrenia: Results from a 12 month double-blind study. European Neuropsychopharmacology 2002;12(Suppl 3):S302. [3090146]
301. Rein W, Fleurot O. Safety of amisulpride vs risperidone in the long-term treatment of chronic schizophrenia: Results from a 12 month double-blind study. European Neuropsychopharmacology 2002;12(Suppl 3):S309. [3090147]
302. Revicki D, Genduso LA, Hamilton SL, Martin C, Reblando J, Tran PV. Quality of life outcomes for olanzapine and haloperidol treatment for schizophrenia and related psychotic disorders. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9, New York, New York, USA. 1996. [3090149]
303. Riedel M, Möller HJ, Müller N. Rational and efficacy of cox-2-inhibitors as adjunctive therapy in schizophrenia. European Neuropsychopharmacology 2003;13(4):S96. [3090151]
304. Schmechtig A, Dourish C, Craig K, Dawson GR, Williams S, Deakin W, Lees J, Wilkinson L, Ettinger U. Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by high schizotypy. Pharmacopsychiatry 2011;21:A99. [4295829]
305. Siever LJ, Koenigsberg HW, Mitropoulou V, Goodman M, Buchsbaum MS. Neurobiology and pharmacologic treatment of schizotypal personality: implications for pharmacology. Proceeding of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [3090155]
306. Tollefson G, Beasley C, Tran P, Dellva MA, Krueger J, Tamura R. Olanzapine versus haloperidol: acute results of the multicenter international trial. Psychopharmacology Bulletin 1996;32(3):401. [3090157]
307. Tollefson G, Beasley C, Tran P, Sanger T. Olanzapine: an exciting atypical antipsychotic; the clinical experience. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30-Oct 4; Venice, Italy. 1995. [3090158]
308. Tollefson G, Lu Y. Comorbid mood disturbance in schizophrenia. Schizophrenia Research 1997;24:192. [3090159]
309. Tollefson GD. Olanzapine: a novel antipsychotic with a broad spectrum profile. Neuropyschopharmacology 1994;10(Suppl 3 Pt 1):805S. [3090179]
310. Tollefson GD. The value of atypical antipsychotic medications. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA. 1997. [3090180]
311. Tollefson GD. Treatment consideration for comorbid mood disorders in schizophrenic patients. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France. 1997. [3090181]
312. Tollefson GD. Update on new atypical antipsychotics. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30-Oct 4; Venice, Italy. 1995. [3090182]
313. Tollefson GD, Andersen SW. Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?. Journal of Clinical Psychiatry 1999;60(Suppl 5):23-9. [3090161]
314. Tollefson GD, Andersen SW, Tran PV. The course of depressive symptoms in predicting relapse in schizophrenia: a double blind, randomized comparison of olanzapine and risperidone. Biological Psychiatry 1999;46(3):365-73. [3090160]
315. Tollefson GD, Beasley CM, Tamura RN, Tran PV, Potvin JH. Blind, controlled, long term study of the comparative incidence of treatment emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry 1997;154(9):1248-54. [3090162]
316. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry 1997;154(4):457-65. [3090163]
317. Tollefson GD, Lu Y. Comorbid mood disturbance in schizophrenia. Biological Psychiatry 1997;41:101S. [3090165]
318. Tollefson GD, Lu Y. Comorbid mood disturbance in schizophrenia. Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996. [3090166]
319. Tollefson GD, Lu Y. Comorbid mood disturbance in schizophrenia. Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21-25; Amsterdam, Netherlands. 1996. [3090167]
320. Tollefson GD, Lu Y, Sanger TM, Beasley CM, Tran PV. Olanzapine in the treatment of schizoaffective disorder. Schizophrenia Research 1997;24(1, 2):92-3. [3090164]
321. Tollefson GD, Sanger TD, Lieberman JA. Olanzapine versus haloperidol in the treatment of first episode psychosis. Biological Psychiatry 1997;41:73S. [3090168]
322. Tollefson GD, Sanger TM. A blinded trial on the course and relationship of depressive symptoms in schizophrenia. Schizophrenia Research 1998;29(1, 2):205. [3090175]
323. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry 1997;154(4):466-74. [3090176]
324. Tollefson GD, Sanger TM, Beasley CM. The course of primary and secondary negative symptoms in a controlled trial with olanzapine. 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996. [3090170; MEDLINE: 97245664]
325. Tollefson GD, Sanger TM, Beasley CM. The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9, New York, New York, USA. 1996. [3090171]
326. Tollefson GD, Sanger TM, Beasley CM. The course of primary and secondary negative symptoms in a controlled trial with olanzapine. Schizophrenia Research 1997;24(1, 2):192. [3090172]
327. Tollefson GD, Sanger TM, Beasley CM. The course of primary and secondary negative symptoms in a placebo- and comparator-controlled trial of the typical antipsychotic olanzapine. Proceedings of the 9th European College of Neuropsychopharmacology Congress; 1996 Sep 21-25; Amsterdam, Netherlands. 1996. [3090173]
328. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A double blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biological Psychiatry 1998;43(11):803-10. [3090169]
329. Tollefson GD, Sanger TM, Leiberman JA. Olanzapine versus haloperidol in the treatment of first episode psychosis. Schizophrenia Research 1997;24(1, 2):193. [3090174]
330. Tollefson GD, Tran PV, Hamilton S, Kuntz A. Olanzapine versus risperidone in the treatment of psychosis. Preliminary report. Biological Psychiatry 1997;41:20S. [3090177]
331. Tollefson GD, Tran PV, Hamilton S, Kuntz A. Olanzapine versus risperidone in the treatment of psychosis. Preliminary report. Schizophrenia Research 1997;24(1, 2):191-2. [3090178]
332. Tran P, Beasley C, Street J, Tamura R, Dellva MA, Graffeo K, et al. Olanzapine versus haloperidol: acute results of the multi-center international trial. Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996. [3090184]
333. Tran P, Beasley C, Tollefson G, Beuzen J, Dellva M, Sanger T, et al. Acute and long-term results of the North American double-blind olanzapine trial. Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30-Oct 4; Venice, Italy. 1995. [3090185]
334. Tran P, Beasley C, Tollefson G, Crawford A, Dellva M, Gusman S, et al. Acute and long-term results of the dose ranging double-blind olanzapine trial. Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996. [3090186]
335. Tran P, Lu Y, Sanger T, Beasley C, Tollefson G. Olanzapine in the treatment of schizoaffective disorder. Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 Jul 12-16; Glasgow, UK. 1998. [3090187]
336. Tran P, Sanger TM, Satterlee W, Beasley CJr, Tamura RN, Tollefson GD. Olanzapine vs haloperidol - results of a large multi-centre international trial. Proceedings of the 4th International Conference on Schizophrenia - 1996: Breaking down the Barriers; 1996 Oct 6-9; Vancouver, Canada. 1996. [3090188]
337. Tran PV, Basson BR, Kennedy JS, Beasley Jr CM, Bymaster FP, Tollefson GD. The comparative anti-muscarinic-like side effect profiles of olanzapine and risperidone treatment in patients with schizophrenia spectrum psychosis. European Neuropsychopharmacology 1999;9:S290. [3090189]
338. Tran PV, Beasley CM, Tollefosn GD, Sanger T, Satterlee WG. Clinical efficacy and safety of olanzapine, a new atypical antipsychotic agent. Neuropsychopharmacology 1994;10(3S):267S. [3090190]
339. Tran PV, Beasley CM, Tollefson GD, Beuzen JN, Holman SL, Sanger TM, et al. Olanzapine: a promising "atypical" antipsychotic agent. Schizophrenia Research 1995;15(1, 2):169. [3090191]
340. Tran PV, Dellva MA, Beasley CM Jr, Satterlee WG, Cousins LM, Tollefson GD. Clinical experience with long-term continuation treatment with olanzapine. Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9, New York, New York, USA. 1996. [3090192]
341. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry 1997;58(5):205-11. [3090193]
342. Tran PV, Hamiliton SH, Kuntz AJ, Tollefson GD. Olanzapine versus risperidone in the treatment of psychosis disorders: a preliminary report. Proceedings of the 35th Annual Meeting of the American College of Neuropsychopharmacology; 1996 Dec 9-13; San Juan, Puerto Rico. 1996. [3090194]
343. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology 1997;17(5):407-18. [3090195]
344. Tran PV, Tollefson GD, Andersen SW, Kuntz AJ, Hamilton SH. Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria. 1997. [3090196]
345. Tran PV, Tollefson GD, Anderson SW, Kuntz A, Hamilton SH. Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Schizophrenia Research 1998;29(1, 2):205. [3090197]
346. Tran PV, Tollefson GD, Crawford AM, Dossenbach M, Friedel P, Folnegovic V, et al. Olanzapine versus fluphenazine in schizophrenia. Proceedings of the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Ontario, Canada. 1998. [3090198]
347. Tran PV, Tollefson GD, Hamilton S. Olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, California, USA. 1997. [3090200]
348. Tran PV, Tollefson GD, Hamilton S, Kuntz A. Olanzapine vs. risperidone in the treatment of psychosis. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France. 1997. [3090199]
349. Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-Methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 2004;55(5):452-6. [3090202]
350. Tsai GE, Yang P, Chang Y-C, Chong M-Y. D-alanine added to antipsychotics for the treatment of schizophrenia. Biological Psychiatry 2006;59(3):230-4. [3090204]
351. Urioste R, Bossie C, Zhu Y, Ciliberto N, Trinh B, Lasser R. Clinical improvement with long-acting risperidone: no impact of race. Proceedings of the 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-6; New York, New York, USA. 2004. [3090206]
352. Wang G. 60 week, randomized, double-blind, placebo-controlled trial of valproate added to risperidone in 200 treatment-naive, first-episode patients with schizophrenia. Stanley Foundation Research Programs 2003. [3090208]
353. Weickert TW, Goldberg TE, Marenco S, Bigelow LB, Egan MF, Weinberger DR. Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds. Neuropsychopharmacology 2003;28(8):1491-500. [3090210]
354. Weiden P, Radulovic L, Wang C, Allison D. Sibutramine for the treatment of obesity in schizophrenia: randomized, placebo controlled pilot study. 2005. [4295831]
355. Wirshing DA, Marshall BD Jr, Green MF, Mintz J, Marder SR, Wirshing WC. Risperidone in treatment-refractory schizophrenia. American Journal of Psychiatry 1999;156(9):1374-9. [3090212]
356. Wirshing WC, Ames D, Green M, Marshall BD, Marder SR. Risperidone versus haloperidol in treatment-refractory schizophrenia: preliminary results. Psychopharmacology Bulletin 1995;31(3):633. [3090213]
357. Wirshing WC, Ames D, Marder SR, Marshall BD, Green MF, McGurk S. Risperidone vs haloperidol in treatment resistant schizophrenia: preliminary results. Schizophrenia Research 1996;18(2, 3):130. [3090214]
358. Wirshing WC, Ames D, Marder SR, Marshall BD, Green MF, McGurk SR. Risperidone in treatment resistant schizophrenia. Proceedings of the 34th Annual Meeting of the American College of Neuropsychopharmacology; 1995 Dec 11-15; San Juan, Puerto Rico. 1995. [3090215]
359. Wirshing WC, Ames D, Marshall BD, Green MF, McGurk S. Risperidone in treatment resistant schizophrenia. Proceeding of the 8th Biennial Winter Workshop on Schizophrenia; 1996 Mar 16-22; Crans Montana, Switzerland. 1996. [3090216]
360. Wirshing WC, Ames D, Palmer Bray M, Marshall BD, Green MF, Marder SR. Risperidone versus haloperidol in treatment refractory schizophrenia: preliminary results. Proceeding of the 148th Annual Meeting of the American Psychiatric Association; 1995 May 20-25; Miami, Florida, USA. 1995. [3090217]
361. Wirshing WC, Green MF, Ames D, Marshall BD, McGurk SR, Mintz J, et al. Risperidone vs. haloperidol in treatment-resistant schizophrenia. Proceedings of the 6th World Congress of Biological Psychiatry; 1997 Jun 22-27; Nice, France. 1997. [3090218]
362. Yamawaki S, Hayashi T, Yokota N, Takahashi T, Sato G, Tahara Y. Serotonin-dopamine antagonists in elderly schizophrenics. Proceedings of the 20th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1996 Jun 23-27; Melbourne, Australia. 1996. [3090220]
363. Zhang CZ. A study of the therapeutic effectiveness of risperidone in combination with antioxidants in the treatment of schizophrenia. Herald of Medicine 2002;21(10):629-30. [3090222]
364. Zhong Z-Y, Tao J, Wang X-L, Wu X-L, Zhang J-B. Effect of antipsychotic plus buflomedil hydrochloride in ameliorating the negative symptoms of patients with schizophrenia. Chinese Journal of Clinical Rehabilitation [Zhongguo lin chuang kang fu] 2006;10(2):30-2. [3090224]
365. Anon An assessment of the long-term efficacy and safety of org 5222, risperidone and placebo in subjects with schizophrenia. http://www.clinicalstudyresults.org/ (2010). [3090226]
366. Bose A, Li D, Migliore R, Werner P, Nemeth G, Laszlovsky I. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. European Psychiatry 2011;26(1):1354. [3089883]
367. Bose A, Li D, Migliore R, Werner P, Nemeth G, Laszlovszky I. The efficacy and safety of the novel antipsychotic cariprazine in acute exacerbation of schizophrenia. European Neuropsychopharmacology 2010:493-4. [3089884]
368. Cavazzoni P, Berg P, Millikan M, Carlson C, Beasley C. An integrated analysis of treatment-emergent extrapyramidal syndrome in schizophrenic patients during olanzapine clinical trials versus placebo, haloperidol, risperidone or clozapine. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S164. [3089916]
369. Cavazzoni P, Berg PH, Millikan M, Carlson C, Beasley CM. An integrated analysis of treatment-emergent extrapyramidal syndrome in schizophrenic patients during olanzapine clinical trials versus placebo, haloperidol, risperidone or clozapine. Schizophrenia Research 2002;53(3 Suppl 1):171. [3089917]
370. DeMartinis NA. Results of a phase 2a proof-of-concept trial with a pde10a inhibitor in the treatment of acute exacerbation of schizophrenia. Biological Psychiatry 2012;8(Suppl 1):17S-8S. [3089983]
371. NCT00049946 A multicenter, double-blind, double-dummy, placebo-controlled, randomized, parallel group evaluation of the efficacy and safety of a fixed-dose of talnetant versus placebo versus risperidone in subjects with schizophrenia. clinicaltrials.gov/show/NCT00049946 (2002). [3090013]
372. NCT00103727 A multicenter, double-blind, double-dummy, placebo-controlled, randomized, parallel group evaluation of the efficacy and safety of a fixed-dose of talnetant versus placebo versus risperidone in subjects with schizophrenia. clinicaltrials.gov/show/NCT00103727 (2005). [3090014; NCT00103727]
373. NCT00300963 A multicenter, double-blind, double-dummy, placebo-controlled, randomized, parallel group evaluation of the efficacy and safety of a fixed-dose of talnetant versus placebo versus risperidone in subjects with schizophrenia. clinicaltrials.gov/show/NCT00300963 (2006). [3090015; NCT00300963]
374. Litman R, Smith M, Doherty J, Cross A, Raines S, Zukin S. AZD8529, a positive allosteric modulator at the MGGLUR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. European neuropsychopharmacology 2014;24:S508-S509. [4295833]
375. Litman RE, Smith MA, Doherty J, Cross A, Raines S, Zukin S. AZD8529, a positive allosteric modulator at the mGLuR2 receptor, does not improve symptoms in schizophrenia: A proof of principle study. Schizophrenia research 2014;153:S176. [4295834]
376. NCT00921804 Study to assess the efficacy, safety, and tolerability of AZD8529 in adult schizophrenia patients. clinicaltrials.gov/show/NCT00921804 (2009). [4295835]
377. Debelle M, Faradzs-zade S, Szatmari B, Nagy K, Nemeth G, Durgam S, Laszlovszky I. Cariprazine in negative symptoms of schizophrenia: Post hoc analyses of a fixed-dose, placebo-and active-controlled trial. European neuropsychopharmacology 2014;24:S534. [4295837]
378. NCT01086748 A study in schizophrenia patients. ClinicalTrials.gov/show/NCT01086748 (2010). [3090132]
379. NCT01175135 An inpatient study of the efficacy, safety, and tolerability of pf-02545920 in the treatment of acute exacerbation of schizophrenia. ClinicalTrials.gov/show/NCT01175135 (2010). [3090134]
380. NCT01363349 Phase iib-iii study of bl-1020 small molecule for schizophrenia. ClinicalTrials.gov/show/NCT01363349 (2011). [3090136]
381. Nisenbaum L, Millen B A, Zhao F, Downing A, Quigley A, Kohler J, et al. LY 2140023 monohydrate in the treatment of patients with schizophrenia: Pharmacogenetic analysis within a clinical trial assessing efficacy in treating acutely ill patients. Schizophrenia Bulletin 2013;39:S105. [3090230]
382. Rujescu D. Riluzole for schizophrenia. Stanley Foundation Research Programs 2009. [3090153]
383. Nct02469155 A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment. https://ClinicalTrials.gov/show/NCT02469155 2015. [4295839]
384. Vanover K, Davis RE, Ereshefsky L, Mates S. Positive results with ITI-007 for the treatment of schizophrenia: A randomized double-blind placebo- and active-controlled phase 2 study. Schizophrenia research 2014;153:S278-S279. [4295840]
385. Vanover KE, Davis RE, Mates S. ITI-007 for the treatment of schizophrenia: A differentiating response profile. Biological psychiatry 2014;1:325S. [4295841]
386. Vanover KE, Davis RE, Mates S. ITI-007, a new approach to the treatment of schizophrenia. Schizophrenia research 2014;153:S21. [4295842]
387. Vanover KE, Mates S, Greengard P, Davis RE. Phase 2 evaluation of ITI-007, a novel approach to the treatment of schizophrenia. Neuropsychopharmacology 2013;38:S386-S387. [4295843]
388. Xu Z. LDXGW for schizophrenia. Stanley Foundation Research Programs 2009. [3090232]
389. NCT00174200 A randomized, double-blind, crossover add-on study to assess the differential sensitivity of 2 spatial working memory tests (the groton maze learning test [gmlt] and the motor delayed response test [mdr]) in non-agitated, antipsychotic drug-naive first-episode schizophrenic or schizophreniform patients treated with risperidone 2 mg daily or placebo. clinicaltrials.gov/show/NCT00174200 (2005). Date accessed: 9/10/2013. [3090234]
390. Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI:10.1002/14651858.CD003082.pub3 ; PUBMED: 24242360]
391. Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. British Journal of Psychiatry 1993;22:39-44.
392. Ahmed U, Rehman F, Jones H, Adams Clive E. Risperidone for psychosis induced aggression or agitation. Cochrane Database of Systematic Reviews 2011, Issue 11. [DOI: 10.1002/14651858.CD009412; CD009412]
393. Hassner VS. Scientific fraud: Eric Poehlman / Richard Borison. Alliance for Human Research Protection (http://www.ahrp.org/cms/content/view/370/29/) 29 Oct 2006 (accessed 5 Nov 2009).
394. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
395. Andreasen, NC Scale for the assessment of negative symptoms: SANS. Lowa: the University of Lowa. 1981.
396. Asmal L, Flegar SJ, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD006625.pub3; PUBMED: 24249315]
397. Bagnall A, Fenton M, Kleijnen J, Lewis R. Molindone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI:10.1002/14651858.CD002083.pub2 ; PUBMED: 17253473]
398. Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-6.
399. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276(8):637-9.
400. Belgamwar RB, El-Sayeh HG. Aripiprazole versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 8. [DOI:10.1002/14651858.CD006622.pub2 ; PUBMED: 21833956]
401. Benson H, Friedman R. Harnessing the power of the placebo effect and renaming it "remembered wellness". Annual Review of Medicine 1996;47:193-9.
402. Bhattacharjee J, El-Sayeh HG. Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 3. [DOI:10.1002/14651858.CD006617.pub3 ; PUBMED: 18646161]
403. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
404. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
405. Carpenter WT Jr, Buchanan RW. Schizophrenia. The New England Journal of Medicine 1994;330(10):681-90.
406. Carpenter WT, Appelbaum PS, Levine RJ. The Decleration of Helsinki and clinical trials: a focus on placebo-controlled trials in schizophrenia. American Journal of Psychiatry 2003;160(2):356-62.
407. Augusta G. Drug money: Patients worsened; little oversight provided. CBS News (http://www.cbsnews.com/stories/2000/07/31/48hours/main220233.shtml) 31 Jul 2000 (accessed 5 November 2009).
408. Chouinard G, Arnott W. Clinical review of risperidone. Canadian Journal of Psychiatry 1993;38(Suppl 3):89-95.
409. Darby JK, Pasta DJ, Elfand L, Dabiri L, Clark L, Herbert J. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. Journal of Clinical Psychopharmacology 1997;17(6):478-84.
410. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
411. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
412. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
413. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Washington, DC: American Psychiatric Association, 1994.
414. Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 2. [DOI:10.1002/14651858.CD001359.pub2; PUBMED: 15846619]
415. Egger M, Davey-Smith G, Schneider M, Minder CSO. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;13:629-34.
416. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
417. Gilbody SM, Bagnall AM, Duggan L, Tuunainen A. Risperidone versus other atypical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD002306]
418. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
419. Guy U. ECDEU assessment manual for psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
420. Heykants J, Huang ML, Mannens G, Meuldermans W, Snoeck E, Van Beijsterveldt L, et al. The pharmacokinetics of risperidone in humans: a summary. Journal of Clinical Psychiatry 1994;55(Suppl):13-7.
421. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
422. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Chichester: John Wiley & Sons, 2008.
423. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Available from www.cochrane-handbook.org: The Cochrane Collaboration, 2011.
424. Hosalli P, Davies JM. Depot risperidone for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 4. [DOI: 10.1002/14651858.CD004161]
425. Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI:10.1002/14651858.CD000440]
426. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
427. Hutton P, Morrison AP, Yung AR, Taylor PJ, French P, Dunn G. Effects of drop-out on efficacy estimates in five Cochrane reviews of popular antipsychotics for schizophrenia. Acta Psychiatrica Scandinavicia 2012;126(1):1-11. [DOI:10.1111/j.1600-0447.2012.01858.x ; PUBMED: 22486554]
428. Jayaram MB, Hosalli P, Stroup S. Risperidone versus olanzapine for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 2. [DOI: 10.1002/14651858.CD005237]
429. Jayaram MB, Hosalli PM, Stroup TS. Risperidone versus olanzapine for treatment of schizophrenia. Schizophrenia Bulletin 2007;33(6):1274-6. [PUBMED: 17921477]
430. Joy CB, Adams CE, Lawrie SM. Haloperidol versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD003082.pub2]
431. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
432. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
433. Kennedy E, Song F, Hunter R, Clarke A, Gilbody S. Risperidone versus typical antipsychotic medication for schizophrenia. Cochrane Database of Systematic Reviews 2000, Issue 2. [DOI:10.1002/14651858.CD003082.pub2]
434. Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD006569.pub5; PUBMED: 24385408]
435. Komossa K, Rummel C, Hunger H, Schmidt F, Schwarz S, Leucht S. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD006626.pub2]
436. Komossa K, Rummel-Kluge C, Hunger H, Schwarz S, Schmidt F, Lewis R, et al. Sertindole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 2. [DOI: 10.1002/14651858.CD006752.pub2; PUBMED: 19370652]
437. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, et al. Amisulpride versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD006624.pub2; PUBMED: 20091599]
438. Kumar A, Strech D. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database of Systematic Reviews 2005, Issue 4. [DOI:10.1002/14651858.CD005474 ; PUBMED: 16235403]
439. Laughren TP. The scientific and ethical basis for placebo-controlled trials in depression and schizophrenia: an FDA perspective. European Psychiatry 2001;16(7):418-23.
440. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71.
441. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8.
442. Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. Journal of Clinical Psychiatry 1994;55(Suppl):5-12.
443. Li C, Xia J, Wang J. Risperidone dose for schizophrenia. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: 10.1002/14651858.CD007474.pub2]
444. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a crosssectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;76((suppl. 334)):1-100.
445. Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. The New England Journal of Medicine 1997;337:853-6.
446. Lurie P, Greco DB. US exceptionalism comes to research ethics. The Lancet 2005;365:1117-9.
447. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
448. Mota NE, Lima MS, Soares BG. Amisulpride for schizophrenia. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD001357; PUBMED: 12076408]
449. Nussbaum AM, Stroup TS. Paliperidone palmitate for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 6. [DOI: ; PUBMED: 22696377]
450. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
451. Pietrzak RH, Maruffb P, Mayesc LC, Romand SA, Sosad JA, Snyde PJ. An examination of the construct validity and factor structure of the Groton Maze Learning Test, a new measure of spatial working memory, learning efficiency, and error monitoring. Archives of Clinical Neuropsychology 2008;23(4):433-45.
452. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
453. Simpson GM, Angus JWS. A rating scale for extrapyramidal side-effects. Acta Psychiatrica Scandinavica Supplementum 1970;212:11-9.
454. Vallance AK. Something out of nothing: the placebo effect. Advances in Psychiatric Treatment 2006;12:287-96.
455. World Medical Association. Ethical principles for medical research involving human subjects. World Medical Association 2008.
456. Xia J, Adams C, Bhagat N, Bhagat V, Bhoopathy P, El-Sayeh H, et al. Losing participants before the trial ends erodes credibility of findings. Psychiatric Bulletin 2009;33:254-7.